Medical Oncology

Vanderbilt

Questions discussed in this category

For persistent localized muscle-invasive bladder cancer following chemoradiation in patients who are not surgical candidates, what is an appropriate next therapy?

1 Answer available

As consolidative thoracic radiation (cTRT) was prohibited on the seminal chemoimmunotherapy trials in ES-SCLC, how do you approach cTRT in practice?

Would you consider it for a patient who had bulky thoracic disease, only a single extrathoracic site of involvement and achieved a CR after induction ...

2 Answers available

For extensive stage small cell lung cancer, are there any data to guide choice of immunotherapy agent in first line treatment (ie chemo/durvalumab vs chemo/atezolizumab)?

Is immunotherapy plus chemotherapy now standard of care for small cell lung cancer, even though overall survival differences are small? Are there any ...

1 Answer available

Would you consider checkpoint inhibitor therapy alone in a patient with metastatic NSCLC with PDL-1 < 1% who is otherwise refusing chemotherapy?

Would nivo + Ipi be appropriate in this situation, especially if high TMB?

4 Answers available

What is the role for "liquid biopsy" for patients with newly diagnosed metastatic NSCLC?

Especially in light of the new Guardant data presented at AACR 2019

2 Answers available

With the FDA approval of third line pembrolizumab for patients with SCLC, how would you select a candidate for pembrolizumab or nivolumab in the third line management of SCLC?

1 Answer available

When do you recommend broader molecular testing for clinical trials in stage IV NSCLC patients who have negative initial molecular testing for FDA-approved targetable mutations?

1 Answer available

For pre-menopausal patients with high-risk ER+ disease, and who desire pregnancy, what is the best time frame to pause endocrine therapy to allow for pregnancy?